

Published in final edited form as:

Science. 2013 November 15; 342(6160): 866–871. doi:10.1126/science.1243292.

Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage

Ivan Angulo^{1,†}, Oscar Vadas^{2,†,#}, Fabien Garçon^{3,†}, Edward Banham-Hall^{3,†}, Vincent Plagnol⁴, Timothy R. Leahy^{5,6}, Helen Baxendale⁷, Tanya Coulter^{6,8}, James Curtis¹, Changxin Wu¹, Katherine Blake-Palmer¹, Olga Perisic², Deborah Smyth⁹, Mailis Maes¹, Christine Fiddler¹, Jatinder Juss¹, Deirdre Cilliers¹⁰, Gašper Markelj¹¹, Anita Chandra⁷, George Farmer¹², Anna Kielkowska¹³, Jonathan Clark¹³, Sven Kracker^{14,15}, Marianne Debré¹⁶, Capucine Picard^{15,16,17}, Isabelle Pellier¹⁸, Nada Jabado¹⁹, James A. Morris²⁰, Gabriela Barcenas-Morales²¹, Alain Fischer^{14,15,16}, Len Stephens³, Phillip Hawkins³, Jeffrey C. Barrett²⁰, Mario Abinun⁵, Menna Clatworthy¹, Anne Durandy^{14,15,16,17}, Rainer Doffinger⁷, Edwin Chilvers¹, Andrew J. Cant⁵, Dinakantha Kumararatne⁷, Klaus Okkenhaug³, Roger L. Williams², Alison Condliffe^{1,‡}, and Sergey Nejentsev^{1,‡,*}

¹Department of Medicine, University of Cambridge, Cambridge, UK ²Medical Research Council, Laboratory of Molecular Biology, Cambridge, UK ³The Babraham Institute, Cambridge, UK ⁴University College London Genetics Institute, University College London, London, UK ⁵Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK ⁶Our Lady's Children's Hospital, Crumlin, Dublin, Ireland ⁷Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK ⁸Department of Immunology, School of Medicine, Trinity College Dublin, Ireland ⁹Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK ¹⁰Department of Clinical Genetics, Oxford University Hospitals, Oxford, UK ¹¹Department of Allergy, Rheumatology and Clinical Immunology, University Children's Hospital, University Medical Center, Ljubljana, Slovenia ¹²Raigmore Hospital, Inverness, UK ¹³Babraham Bioscience Technologies Ltd, Babraham Research Campus, Cambridge, UK ¹⁴National Institute of Health and Medical Research INSERM U768, Necker Children's Hospital, F-75015 Paris, France ¹⁵Descartes-Sorbonne Paris Cité University of Paris, Imagine Institute, France ¹⁶Department of Immunology and Hematology, Assistance Publique-Hopitaux de Paris, Necker Children's Hospital, F-75015 Paris, France ¹⁷Center for Primary Immunodeficiencies (CEDI), Assistance Publique-Hopitaux de Paris, Necker Children's Hospital, F-75015 Paris, France ¹⁸Department of Pediatrics, Centre Hospital Universitaire, F-49000 Angers, France ¹⁹Department of Pediatrics, McGill University and McGill University Health Center Montreal, Canada ²⁰Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1HH, UK ²¹Laboratorio de Inmunologia, Unam, Fes-Cuautitlan, Mexico

Abstract

Genetic mutations cause primary immunodeficiencies (PIDs), which predispose to infections. Here we describe Activated PI3K- δ Syndrome (APDS), a PID associated with a dominant gain-of-function mutation E1021K in the p110 δ protein, the catalytic subunit of phosphoinositide 3-kinase δ (PI3K δ), encoded by the *PIK3CD* gene. We found E1021K in 17 patients from seven unrelated

*Correspondence to: sn262@cam.ac.uk.

†joint first authorship

‡joint senior authorship

#Current address: Department of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland

families, but not among 3,346 healthy subjects. APDS was characterized by recurrent respiratory infections, progressive airway damage, lymphopenia, increased circulating transitional B cells, increased IgM and reduced IgG2 levels in serum and impaired vaccine responses. The E1021K mutation enhanced membrane association and kinase activity of p110 δ . Patient-derived lymphocytes had increased levels of phosphatidylinositol 3,4,5-trisphosphate and phosphorylated AKT protein and were prone to activation-induced cell death. Selective p110 δ inhibitors IC87114 and GS-1101 reduced the activity of the mutant enzyme *in vitro*, suggesting a therapeutic approach for patients with APDS.

Respiratory infections are the most common illnesses of people worldwide. Recurrent respiratory infections may lead to bronchiectasis, a permanent, abnormal dilation of bronchi (1). Susceptibility to recurrent respiratory infections and bronchiectasis may be conferred by an underlying primary immunodeficiency (PID) (1, 2). PIDs have variable penetrance and those that have a milder course may remain undiagnosed. Mutations in more than 200 genes are known to cause various PIDs (3). Recent improvements in DNA sequencing technology provide an opportunity to study the patient's whole genome or its coding part, known as the exome (4). This technological advancement has significantly improved the genetic diagnostics of PIDs in patients with recurrent and severe infections and facilitated the identification of novel causative genes and mutations.

We used exome sequencing to search for causative mutations in 35 PID patients from the UK who suffered recurrent infections and had a family history of susceptibility to infections (5). Following identification of genetic variants in these patients, we excluded common polymorphisms previously detected in the 1,000 Genomes and NHLBI projects (table S1) (5). When cross-checking the remaining rare variants, we noted that three patients from one family (P1, P2 and P3 in family A) and one patient from another family (P5 in family B) had the same heterozygous G to A mutation at position 9,787,030 on chromosome 1, c.3061G>A in the *PIK3CD* gene (fig. 1). This mutation was not present in the other exomes and was the only rare variant shared among all patients in these two unrelated families. It encodes an amino-acid substitution, a glutamic acid for a lysine, at position 1021 (E1021K) of the p110 δ protein, the catalytic subunit of phosphoinositide 3-kinase δ (PI3K δ). Sanger sequencing confirmed the presence of the E1021K mutation in these patients and four additional affected family members. In both families the mutation co-segregated with the clinical phenotype (fig. 1).

We then designed a genotyping assay for this E1021K mutation and screened 3,346 healthy subjects, including 2,296 from the UK and 1,050 representing 51 different populations from around the world (5). No healthy carriers of E1021K were identified in these two large cohorts, supporting our hypothesis that this is a pathogenic mutation rather than a rare neutral polymorphism. We then studied DNA samples of an additional heterogeneous cohort of 134 PID patients from the UK and Ireland (5). In this cohort we identified five further patients from three unrelated families C, D and E who had the same heterozygous E1021K mutation (fig. 1A). The apparent high frequency of the mutation among PID patients and the fact that P8 (family C) had previously been diagnosed with hyper-IgM syndrome prompted us to study an additional cohort from France comprising 15 hyper-IgM patients from 13 families that had previously undergone exome sequencing. Among these we found three patients from two unrelated families F and G with the same mutation, indicating that E1021K may cause a typical hyper-IgM syndrome. One additional patient was identified among family members, bringing the overall number of patients with the E1021K mutation to 17.

Sequencing of the healthy parents of P8 in family C showed that both were homozygous for the normal allele (fig. 1A). Genome-wide identity-by-descent analysis in family C

confirmed the relationship of both parents to P8, thus classifying this E1021K mutation as *de novo*. The mutation was present in DNA isolated from both fibroblast and blood samples of P8 and therefore is likely to be germline, rather than somatic. Then, in families A – E we studied genotypes of 149 markers in a 2 Mb interval on chromosome 1 flanking the mutation (5). We found no shared long-range haplotypes across any pair of families and no flanking markers that were consistently in linkage disequilibrium with the mutation across all five families. These data strongly suggest a recurrent mutation, rather than a founder effect. Nucleotide G in position 9,787,030 is part of a CpG dinucleotide (fig. 1B) that is known to be ~30 times more prone to transition mutations (e.g. G>A) than an average nucleotide in the genome (6).

Prior to our genetic analysis, patients from families A – G were not considered to have the same disease etiology. The discovery of the same causative mutation in these patients prompted us to compare their clinical and immunological histories (table S2), revealing the phenotype of this PID, which is characterized by recurrent respiratory infections and progressive airway damage (table 1, Supplementary Text and figs. S1, S2). Whereas the immunological phenotype was largely consistent between patients, the clinical presentation and disease course have been variable (e.g. mild disease in P10; table S2). Such clinical variability may be explained by differences in lifestyle, exposure to pathogens, treatment efficacy, and possibly by modifying genetic factors.

To understand how the E1021K mutation caused immunodeficiency we first studied its impact on p110 δ function. The p110 δ protein is a catalytic subunit that, together with a regulatory subunit, forms PI3K δ , a heterodimeric lipid kinase. PI3K δ phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP₂), generating phosphatidylinositol 3,4,5-trisphosphate (PIP₃), an important second messenger molecule. We cloned the cDNA of p110 δ and introduced the E1021K change by site-directed mutagenesis. Subsequently, we expressed both normal and mutant p110 δ proteins, together with the regulatory subunit p85 α , in baculovirus-infected insect cells and purified the proteins (fig. S3A). We measured lipid kinase activity using a modified membrane capture assay (7) and found that the basal PIP₃ production by PI3K δ containing the mutant p110 δ ^{E1021K} subunit was up to 6-fold higher than that produced by the wild type PI3K δ (figs. 2A and S3B). After stimulation with a platelet-derived growth factor (PDGF) receptor's bis-phosphorylated peptide (pY), the activity of both wild type and mutant PI3K δ increased, but PIP₃ production by the mutant PI3K δ was still up to 3 times higher (figs. 2A and S3C). We used two structurally related isoform-selective PI3K δ inhibitors, IC87114 and GS-1101 (8, 9), and found that both reduced the activity of the mutant PI3K δ as efficiently as that of the wild type PI3K δ (fig. 2B), suggesting that these compounds may be effective in patients with the E1021K mutation.

To understand the mechanism by which E1021K increases PI3K δ activity, we first modeled the structure of the mutant p110 δ protein (5). p110 δ is organized similarly to other PI3K catalytic subunits (fig. 2C) (10, 11). The E1021K mutation is located in the C-lobe of the kinase domain that interacts with cellular membrane, accommodates lipid substrate and binds the cSH2 domain of the regulatory subunit (fig. 2D). Structural modeling showed that E1021K of p110 δ is positioned similarly to the somatic mutation H1047R of another PI3K isoform, p110 α , which is known to increase PI3K activity in cancer cells by enhancing its association with membranes (12, 13). Therefore, we used a protein-lipid fluorescence resonance energy transfer (FRET) assay to study interaction between lipid vesicles and either wild type p110 δ or the mutant p110 δ ^{E1021K}. We found that p110 δ ^{E1021K} has a much higher basal affinity for lipid vesicles than the wild type p110 δ (fig. 2E). After pY stimulation, the affinity of p110 δ ^{E1021K} was also increased, although the difference with respect to the pY-activated wild type p110 δ was less striking (fig. 2E). These results suggest

that stronger binding to membranes contributes to the increased activity of the mutant p110 δ ^{E1021K} protein. Another potential activating mechanism of E1021K may involve interaction of p110 δ with the regulatory subunit p85 α (14). Our structural model shows that E1021K may impair binding of p110 δ to the inhibitory cSH2 domain (fig. 2D) leading to increased PI3K δ activity. However, it is unlikely to affect binding of another inhibitory p85 α domain, nSH2 (fig. 2D). This is consistent with our observation that pY stimulation further activates the mutant enzyme, probably by removing the nSH2 inhibition.

PI3K δ is expressed predominantly in cells of hematopoietic lineage and is the major PI3K isoform signaling downstream of T and B cell antigen receptors (TCR and BCR), Toll-like receptors (TLRs), co-stimulatory molecules and cytokine receptors in T, B and myeloid cells (15). Therefore, we studied the activity of the mutant PI3K δ *ex vivo* in patients' leukocytes. We measured levels of PIP₃ using a high-performance liquid chromatography – mass spectrometry-based assay (16) in CD4+ and CD8+ T cells isolated from fresh peripheral blood. In both T lymphocyte lineages we found consistently higher PIP₃ levels in patients than in controls prior to stimulation and 10, 20, 30 and 60 seconds after stimulation (fig. 3A). In patient cells treated with IC87114 the levels of PIP₃ were significantly reduced (fig. 3A). Furthermore, in stimulated patients' T cells we found increased levels of phosphorylated AKT protein, a major downstream mediator of PIP₃ signalling (fig. 3B). Levels of p110 δ expression were normal in the patients' T cells (fig. 3B). We then cloned in a retroviral vector the wild-type p110 δ , the mutant p110 δ ^{E1021K} and p110 δ ^{D911A} with mutation D911A that inactivates the kinase domain, and transduced these constructs into T blasts isolated from the p110 δ -knockout mouse (5). After stimulation cells with p110 δ ^{E1021K} had more phosphorylated AKT than other cells (figs. 3C and S4). Together, these results strongly suggest that the E1021K mutation increases PI3K signaling *in vivo* as well as *in vitro*.

To study T cell responses we stimulated purified CD4+ and CD8+ cells with anti-CD3 and anti-CD28 antibodies. Unexpectedly, we observed that both T cell lineages from patients were prone to cell death (figs. 3D and S5A). This phenomenon was reversed by the addition of IC87114 but not IL-2 (figs. 3D and S5B), suggesting that it is caused by the increased PI3K δ activity. Cytokine production following stimulation of T cells was profoundly reduced in the patients and was not rescued by exogenous IL-2 (fig. S6), suggesting that T cell death occurs prior to any significant cytokine response. However, stimulation with CytoStim, which did not induce T cell death, also led to reduced cytokine production by the patients-derived T cells (fig. S7). The propensity to activation-induced cell death (AICD) is consistent with T cell lymphopenia found in our patients. It may relate in part to the increased proportion of T cells with an activated/memory phenotype (table S2) (17). Moreover, given that p110 δ inhibitor reduces AICD of the patient-derived T cells, the activated p110 δ may increase the AICD per se, possibly by enhancing TCR signalling.

In the patients' B lymphocytes we also found increased amounts of phosphorylated AKT, both before and after stimulation, although this analysis was complicated by enhanced protein degradation in the patient-derived cells (fig. S8). Studies in transgenic mice deficient for phosphatase and tensin homologue (PTEN), an enzyme that dephosphorylates PIP₃, have shown that PI3K δ activity, PIP₃ and phosphorylated AKT suppress immunoglobulin class switch recombination (CSR) in B cells. These mice have impaired B cell function, increased IgM, decreased IgG and IgA levels and impaired antibody responses after immunization (18-21). Immunological presentation of our patients resembles this phenotype and indicates a B cell defect. However, normal total IgG and IgA levels that were found in most of our patients suggest that CSR may be only partially affected. Nevertheless, inefficient antibody production impairs responses to *S. pneumoniae* and *H. influenzae type B* vaccinations in our patients leading to recurrent infections with these pathogens. An increased population of

circulating transitional B cells may reflect a block in late stages of B cell maturation or an enhanced death of mature B cells.

PI3K δ is also highly expressed in neutrophils. We found that patient-derived neutrophils retained their ability to undergo a respiratory burst, degranulation, chemotaxis, and apoptosis (fig. S9). We measured PIP₃ accumulation in TNF α -primed neutrophils in response to fMLP stimulation at 6 seconds (a PI3K γ -dependent response) and at 60 seconds (a predominantly PI3K δ -mediated signal) (22) and found no significant difference between patients and controls in either response (fig. S9). Thus, the effect of the E1021K mutation on the PI3K δ activity may be cell-type or stimulus-specific, or may be compensated for by effects of other PI3K isoforms or PTEN. Nevertheless, we cannot exclude that a subtle defect in neutrophil function may contribute to the disease pathogenesis in these patients.

Here we describe a PID caused by a recurrent autosomal dominant germline mutation E1021K in the *PIK3CD* gene that encodes p110 δ . We found it in 17 patients from seven unrelated families, suggesting that it is frequent among PID patients and may explain a substantial fraction of patients with recurrent respiratory infections and bronchiectasis. Our rapid genotyping assay should facilitate screening for the E1021K mutation in existing PID and bronchiectasis cohorts, as well as new patients. The E1021K mutation was previously noted in one Taiwanese patient with recurrent respiratory infections and PID; however, its causative and pathogenic role has not been demonstrated (23). Here we have shown that E1021K increases PI3K δ activity, augmenting the production of PIP₃ and activating the downstream AKT protein in lymphocytes. This leads to defects in T and B cell function and inefficient immune responses to bacterial pathogens, predisposing to recurrent respiratory infections and eventually to bronchiectasis. We named this disorder Activated PI3K-Delta Syndrome (APDS).

Activation of the PI3K pathway is associated with malignant transformations and it has been shown that overexpression of p110 δ can transform cells (24). To date, only one of our APDS patients, P13, has been diagnosed with lymphoma (table 1). Nonetheless, the oncogenic potential of PI3K up-regulation can be enhanced by additional mutations (25, 26). Therefore, APDS patients may be at increased risk of leukemia or lymphoma if they acquire additional somatic mutations.

The APDS patients described here had been treated with immunoglobulin replacement and antibiotics. Despite this, there is evidence of significant airway damage in most cases. Because of progressive severe disease following splenectomy, patient P8 underwent allogeneic hematopoietic stem cell transplantation (HSCT) at the age of 8 years. One year after HSCT his clinical condition had improved dramatically, suggesting that HSCT may be a long-term treatment option for young patients. Nevertheless, our results raise the possibility that selective p110 δ inhibitors, such as GS-1101, may be an alternative effective therapeutic approach in APDS patients. GS-1101 (CAL-101 or Idelalisib) has been tested in phase I/II clinical trials for treatment of chronic lymphocytic leukemia (www.clinicaltrials.gov). The possibility of treating APDS patients with p110 δ inhibitors should therefore be considered.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

S.N. is a Wellcome Trust Senior Research Fellow in Basic Biomedical Science (095198/Z/10/Z). S.N. is also supported by the European Research Council Starting grant 260477 and the EU FP7 collaborative grant 261441

(PEVNET project). S.N., A.C., D.K., and R.D. are supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. O.V. was supported by a Swiss National Science Foundation fellowship (grant no. PA00P3_134202) and a European Commission fellowship (FP7-PEOPLE-2010-IEF, no. 275880). R.L.W. was supported by the Medical Research Council (file reference U105184308). T.C. is supported by the National Children's Research Centre, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland. E.B.H. is supported by a Wellcome Trust Translational Medicine and Therapeutics award. A.C. is supported by the MRC and British Lung Foundation. K.O. is supported by a strategic grant from the Biotechnology and Biological Sciences Research Council and a New Investigator Award from the Wellcome Trust. P.H. and L.S. are funded by an Institute Programme grant from BBSRC (BB/J004456/1). S.K. is a Centre National de la Recherche Scientifique (CNRS) researcher. A.D., A.F. and S.K. are funded by Institut National de la Santé et de la Recherche Médicale, A.D. is supported by the EU FP7 EUROPAD contract 201549, Association Contre Le Cancer and the ANR (grant: 2010-CSRD). A.F. is supported by the EU FP7 ERC PIDIMMUNE grant number 249816. The following are paid consultants for GSK (P.H., L.S., K.O., A.C., E.C.), Karus pharmaceuticals (P.H, L.S.), Roche and Novartis (E.C.). The mutation is submitted to ClinVar database; accession SCV000083058.

References and Notes

1. Barker AF. Bronchiectasis. *N Engl J Med.* 2002; 346:1383. [PubMed: 11986413]
2. Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. *Nat Rev Immunol.* 2013; 13:519. [PubMed: 23765059]
3. Al-Herz W, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. *Front Immunol.* 2011; 2:54. [PubMed: 22566844]
4. Bamshad MJ, et al. Exome sequencing as a tool for Mendelian disease gene discovery. *Nat Rev Genet.* 2011; 12:745. [PubMed: 21946919]
5. Materials and methods are available as supplementary materials on Science online.
6. Hodgkinson A, Eyre-Walker A. Variation in the mutation rate across mammalian genomes. *Nat Rev Genet.* 2011; 12:756. [PubMed: 21969038]
7. Knight ZA, Feldman ME, Balla A, Balla T, Shokat KM. A membrane capture assay for lipid kinase activity. *Nat Protoc.* 2007; 2:2459. [PubMed: 17947987]
8. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. *J Immunol.* 2003; 170:2647. [PubMed: 12594293]
9. Lannutti BJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. *Blood.* 2011; 117:591. [PubMed: 20959606]
10. Scheeff ED, Bourne PE. Structural evolution of the protein kinase-like superfamily. *PLoS Comput Biol.* 2005; 1:e49. [PubMed: 16244704]
11. Vadas O, Burke JE, Zhang X, Berndt A, Williams RL. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. *Sci Signal.* 2011; 4:re2. [PubMed: 22009150]
12. Mandelker D, et al. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. *Proc Natl Acad Sci U S A.* 2009; 106:16996. [PubMed: 19805105]
13. Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). *Proc Natl Acad Sci U S A.* 2012; 109:15259. [PubMed: 22949682]
14. Burke JE, et al. Dynamics of the phosphoinositide 3-kinase p110delta interaction with p85alpha and membranes reveals aspects of regulation distinct from p110alpha. *Structure.* 2011; 19:1127. [PubMed: 21827948]
15. Okkenhaug K. Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells. *Annu Rev Immunol.* 2013; 31:675. [PubMed: 23330955]
16. Clark J, et al. Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. *Nat Methods.* 2011; 8:267. [PubMed: 21278744]
17. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annu Rev Immunol.* 2004; 22:745. [PubMed: 15032595]
18. Anzelon AN, Wu H, Rickert RC. Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. *Nat Immunol.* 2003; 4:287. [PubMed: 12563260]

19. Suzuki A, et al. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. *J Exp Med.* 2003; 197:657. [PubMed: 12615906]
20. Omori SA, et al. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. *Immunity.* 2006; 25:545. [PubMed: 17000121]
21. Janas ML, et al. The effect of deleting p110delta on the phenotype and function of PTEN-deficient B cells. *J Immunol.* 2008; 180:739. [PubMed: 18178811]
22. Condliffe AM, et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. *Blood.* 2005; 106:1432. [PubMed: 15878979]
23. Jou ST, et al. Identification of variations in the human phosphoinositide 3-kinase p110delta gene in children with primary B-cell immunodeficiency of unknown aetiology. *Int J Immunogenet.* 2006; 33:361. [PubMed: 16984281]
24. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. *Proc Natl Acad Sci U S A.* 2006; 103:1289. [PubMed: 16432180]
25. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nat Rev Cancer.* 2009; 9:550. [PubMed: 19629070]
26. Kinross KM, et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. *J Clin Invest.* 2012; 122:553. [PubMed: 22214849]
27. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature.* 2007; 447:661. [PubMed: 17554300]
28. Power C, Elliott J. Cohort profile: 1958 British birth cohort (National Child Development Study). *Int J Epidemiol.* 2006; 35:34. [PubMed: 16155052]
29. Cann HM, et al. A human genome diversity cell line panel. *Science.* 2002; 296:261. [PubMed: 11954565]
30. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. *Nature.* 2012; 491:56. [PubMed: 23128226]
31. Fu W, et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. *Nature.* 2013; 493:216. [PubMed: 23201682]
32. Berndt A, et al. The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. *Nat Chem Biol.* 2010; 6:244. [PubMed: 20154668]
33. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr.* 2010; 66:486. [PubMed: 20383002]
34. Wehr C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. *Blood.* 2008; 111:77. [PubMed: 17898316]
35. Clayton E, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. *J Exp Med.* 2002; 196:753. [PubMed: 12235209]
36. Revy P, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). *Cell.* 2000; 102:565. [PubMed: 11007475]
37. Hayward AR, Mowla R, Harvey B. Defect of neutrophil mobility with dominant inheritance in a family with Waardenberg's syndrome. *Arch Dis Child.* 1981; 56:279. [PubMed: 7247439]




Fig. 1. Families with the E1021K p110δ mutation

(A) ○ and □ - unaffected; ● and ■ - affected; ⊙ and ⊠ - available data indicate recurrent infections. Age at the time of death is shown for patients who died ≤ 30 years of age. *PIK3CD* genotype is shown if known: wt, wild type allele encoding glutamic acid (E1021); mut, mutant allele encoding lysine (K1021). (B) Sequence chromatogram showing heterozygous mutation c.3061G>A in the *PIK3CD* gene leading to the E1021K amino-acid change in p110δ. CpG dinucleotide is underlined.




Fig. 2. *In vitro* activity and structure of p110δ

(A) Basal and pY-stimulated PI3K activity at 20 nM concentration. Graphs are mean ± SD of 3 independent experiments. *P*-values were calculated by two-tailed *t*-test. (B) Inhibition of mutant and wild-type p110δ/p85α as a function of IC87114 or GS-1101 concentration (data are mean ± SD, N=3). (C) Domain organization of p110δ. (D) Structural model of the p110δ/p85α heterodimer. p110δ catalytic subunit (pale green), nSH2 and iSH2 domains of the p85 regulatory subunit (cyan), cSH2 domain (magenta), p110δ activation loop (thick chocolate tube beneath kα12), residue E1021 of p110δ (green spheres) and the analogous residue in H1047R mutant of p110α (cyan spheres). The IC87114 inhibitor bound in the active site is shown in stick representation. (E) Membrane binding of p110δ. FRET between the PI3K complex and Dansyl-PS-containing membrane vesicles in the absence (solid lines) or presence (dashed lines) of the pY peptide (data are mean ± SD, N=3).




Fig. 3. Functional analyses of T cells in patients with APDS

(A) Intracellular PIP₃ levels in CD4⁺ and CD8⁺ T lymphocytes of patients (red squares, N=6) and controls (blue circles, N=5) at indicated times after anti-CD3/anti-CD28 stimulation in the presence or absence of IC87114. The data are expressed as the ratio of the quantity of PIP₃ divided by that of the internal standard (ISD) and normalized according to the cell number. The data show mean \pm SEM. *P*-values were calculated using two-way ANOVA with Bonferroni correction. (B) Representative (N=3) Western blot showing levels of p110 δ , AKT and phospho-AKT (pAKT) proteins in CD4⁺ T cells isolated from fresh blood samples of a healthy control (C) and a patient (P) without stimulation (-) or after 10 min stimulation (+) with anti-CD3 and anti-CD28 antibodies. (C) Representative (N=2) Western blot showing levels of p110 δ , and pAKT proteins in CD4⁺ T cell blasts of a p110 δ knockout mouse transduced with retroviral constructs expressing either GFP or wild-type p110 δ (p110^{WT}) or kinase dead p110 δ (p110^{D911A}) or p110^{E1021K} without stimulation (-) or after stimulation (+) with anti-CD3 antibodies and anti-CD28 antibodies. (D) Quantification of surviving CD4⁺ and CD8⁺ T cells as indicated by % of cells excluding viability dye. Cells of patients (red, N=4) and controls (blue, N=7) were studied without stimulation and after stimulation with anti-CD3/anti-CD28 antibodies and in the presence of IC87114. Each subject was studied in triplicate. The data show mean \pm SEM. *P*-values were calculated using a two-way ANOVA with Sidak's multiple comparisons test.

Table 1
Summary of clinical and immunological features of patients with the E1021K p1108 mutation

Clinical / Immunological manifestation	Patients	Frequency, n / total studied (%)
Recurrent respiratory and ear infections (<i>H. influenzae</i> , <i>S. pneumoniae</i>)	P1-17	17/17 (100)
CT evidence of large (bronchiectasis) or small (mosaic attenuation) airway disease	P1-7,9,11-13,17	12/16 (75)
Splenomegaly (prior to the onset of recurrent infections)	P2,3,5,6,8,9,13-16	10/17 (59)
Skin, salivary gland, lacrimal gland or dental abscess formation, orbital cellulitis	P1,3,5-8,10	7/17 (41)
Infection caused by herpes group viruses (HSV, CMV, VZV, EBV)	P3,8,12,13 (and the deceased sister of P5/P6)	4/17 (24)
Marginal zone lymphoma	P13	1/17 (6)
Low/intermittent low serum IgG2 levels	P2-7,10-13	10/11 (91)
High/intermittent high serum IgM levels	P1-6,8-11,13-16	14/17 (82)
Low levels of anti-pneumococcal antibodies	P1-4,7,9,11-13,17	10/10 (100)
Low levels of anti-Haemophilus Influenzae type B antibodies	P1-4,8,9,12,13	8/10 (80)
Decreased circulating T cells (total CD3+) and/or CD4+ and/or CD8+ T cells	P1-9,13,14,17	12/17 (71)
Decreased circulating B cells (total CD19+)	P2-9,13,14-16	12/17 (71)
Increased circulating transitional B cells (CD19+CD38+IgM+)	P1-4,7-14,16,17	14/16 (88)
Decreased circulating class switched memory B cells (CD19+CD27+IgD-)	P1-3,8,9,12,13,16	8/16 (50)